Reduced Activity of Sphingosine-1-Phosphate Lyase Induces Podocyte-related Glomerular Proteinuria, Skin Irritation, and Platelet Activation

Toxicologic Pathology

Volumn 43, Issue 5, 2015, Pages 694-703

  Schümann, Jens ^a   Grevot, Armelle ^a   Ledieu, David ^a   Wolf, Armin ^a   Schubart, Anna ^a   Piaia, Alessandro ^a   Sutter, Esther ^a   Côté, Serge ^a   Beerli, Christian ^a   Pognan, François ^a   Billich, Andreas ^a   Moulin, Pierre ^a   Walker, Ursula Junker ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

kidney; podocyte dysfunction; sphingosine 1 phosphate lyase

Indexed keywords

LYASE; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE); TAMOXIFEN; 6 [4 (4 BENZYL 7 CHLOROPHTHALAZIN 1 YL) 2 METHYLPIPERAZIN 1 YL]NICOTINO NITRILE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN; LYASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; UNCLASSIFIED DRUG; UREA;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; ENZYMOLOGY; FEMALE; GENETICS; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PODOCYTE; PROTEINURIA; RAT; SKIN; THROMBOCYTE ACTIVATION; ACANTHOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASEMENT MEMBRANE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; ELECTRON MICROSCOPY; ENZYME INHIBITION; EPIDERMIS HYPERPLASIA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GENETIC MODEL; GLOMERULOPATHY; GLOMERULUS CAPILLARY; GRANULOMATOUS INFLAMMATION; HYPERKERATOSIS; INFLAMMATION; KIDNEY TUBULE DISORDER; MESANGIUM CELL; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK ASSESSMENT; SHEEP ERYTHROCYTE; SKIN CELL; SKIN IRRITATION; T CELL DEPLETION; THROMBOCYTE MEMBRANE; THYMUS; THYMUS ATROPHY; TUBULAR DEGENERATION; UREA BLOOD LEVEL;

ALDEHYDE-LYASES; ANIMALS; FEMALE; KIDNEY; MALE; MICE; PLATELET ACTIVATION; PODOCYTES; PROTEINURIA; RATS; SKIN; TAMOXIFEN;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 84935108790     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623314565650     Document Type: Article

References (27)

1. Allende M. L. Bektas M. Lee B. G. Bonifacino E. Kang J. Tuymetova G. Chen W. Saba J. D. Proia R. L. (2011). Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 286, 7348–58.
2. Awad A. S. Rouse M. D. Khutsishvili K. Huang L. Bolton W. K. Lynch K. R. Okusa M. D. (2011). Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int 79, 1090–8.
3. Bagdanoff J. T. Donoviel M. S. Nouraldeen A. Carlsen M. Jessop T. C. Tarver J. Aleem S. Dong L. Zhang H. Boteju L. Hazelwood J. Yan J. Bednarz M. Layek S. Owusu I. B. Gopinathan S. Moran L. Lai Z. Kramer J. Kimball S. D. Yalamanchili P. Heydorn W. E. Frazier K. S. Brooks B. Brown P. Wilson A. Sonnenburg W. K. Main A. Carson K. G. Oravecz T. Augeri D. J. (2010). Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem 53, 8650–62.
4. Bektas M. Allende M. L. Lee B. G. Chen W. Amar M. J. Remaley A. T. Saba J. D. Proia R. L. (2010). Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 285, 10880–9.
5. Billich A. Baumruker T. Beerli C. Bigaud M. Bruns C. Calzascia T. Isken A. Kinzel B. Loetscher E. Metzler B. Mueller M. Nuesslein-Hildesheim B. Kleylein-Sohn B. (2013). Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis. PLoS one 8, e59630.
6. Genter M. B. Van Veldhoven P. P. Jegga A. G. Sakthivel B. Kong S. Stanley K. Witte D. P. Ebert C. L. Aronow B. J. (2003). Microarray-based discovery of highly expressed olfactory mucosal genes: Potential roles in the various functions of the olfactory system. Physiol Genomics 16, 67–81.
7. Hong J. H. Youm J. K. Kwon M. J. Park B. D. Lee Y. M. Lee S. I. Shin D. M. Lee S. H. (2008). K6PC-5, a direct activator of sphingosine kinase 1, promotes epidermal differentiation through intracellular Ca2+ signaling. J Invest Dermatol 128, 2166–78.
8. Ito K. Anada Y. Tani M. Ikeda M. Sano T. Kihara A. Igarashi Y. (2007). Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun 357, 212–7.
9. Kim D. S. Kim S. Y. Kleuser B. Schäfer-Korting M. Kim K. H. Park K. C. (2004). Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal 16, 89–95.
10. Lievens D. von Hundelshausen P. (2011). Platelets in atherosclerosis. Thromb Haemost 106, 827–38.
11. Loetscher E. Schneider K. Beerli C. Billich A. (2013). Assay to measure the secretion of sphingosine-1-phosphate from cells induced by S1P lyase inhibitors. Biochem Biophys Res Commun 433, 345–8.
12. Merrill A. H. Sullards M. C. Allegood J. C. Kelly S. Wang E. (2005). Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 207–24.
13. Obinata H. Hla T. (2012). Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol 34, 73–91.
14. Okamoto Y. Wang F. Yoshioka K. Takuwa N. Takuwa Y. (2011). Sphingosine-1-phosphate-specific G protein-couples receptors as novel therapeutic targets for atherosclerosis. Pharmaceuticals 4, 117–37.
15. Randriamboavonjy V. Badenhoop K. Schmidt H. Geisslinger G. Fisslthaler B. Fleming I. (2009). The S1P2 receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. Basic Res Cardiol 104, 333–40.
16. Ren S. Babelova A. Moreth K. Xin C. Eberhardt W. Doller A. Pavenstädt H. Schaefer L. Pfeilschifter J. Huwiler A. (2009). Transforming growth factor-β2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-β2 by impeding CTGF expression. Kidney Int 76, 857–67.
17. Saba J. D. de la Garza-Rodea A. S. (2013). S1P lyase in skeletal muscle regeneration and satellite cell activation: exposing the hidden lyase. Biochim Biophys Acta 1831, 167–75.
18. Schaper K. (2012). Effekte von Sphingosin-1-phosphat und Analoga Auf die Entzündungsreaktion Und Epidermale Hyperproliferation in Modellen der Psoriasis. Doctoral thesis; University of Hannover, Germany.
19. Schmahl J. Raymond C. S. Soriano P. (2007). PDGF signaling specificity is mediated through multiple immediate early genes. Nat Genet 39, 52–60.
20. Schwab S. R. Pereira J. P. Matloubian M. Xu Y. Huang Y. Cyster J. (2005). Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735–9.
21. Serra D. M. Saba J. D. (2010). Sphingosine-1-phosphate lyase, a key regulator of sphingosine-1-phosphate signaling and function. Adv Enzyme Regul 50, 349–62.
22. Vogel P. Donoviel M. S. Read R. Hansen G. M. Hazlewood J. Anderson S. J. Sun W. Swaffield J. Oravecz T. (2009). Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4, e4112.
23. Vogler R. Sauer B. Kim D. S. Schäfer-Korting M. Kleuser B. (2003). Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous would healing. J Invest Dermatol 120, 693–700.
24. S., Wartewig, R.R.H., Neubert, Properties of ceramides and their impact on the stratum corneum structure: a review. Part 1: ceramides, Skin Pharmacol Physiol, (2007), 20, 220-229
25. Weiler S. Beerli C. Bergsdorf C. Schubart A. Honnappa S. Oberhauser B. Billich A. (2014). Orally active 7-substituted (4-benzyl-phthalazin-1-yl)-2-methyl-piperazin-1-yl]-nicotinonitriles as active-site inhibitors of sphingosine-1-phosphate lyase for the treatment of multiple sclerosis. J Med Chem 57, 5074–84.
26. Yatomi Y Yamamura S. Ruan F. Igarashi Y. (1997). Sphingosine 1-phosphate induces platelet activation and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 272, 5291–7.
27. X.Q., Yu, J., Kramer, L., Moran, E., O’Neill, A., Nouraldeen, T., Oravecz, A.A.E., Wilson, Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate, Xenobiotica, (2010), 40, 350-356